...A. Looking back to last year, we had a very positive Phase III data for eplontersen in TTR amyloidosis with polyneuropathy. B. This year, we had a drug approval, QALSODY, for SOD1-ALS, which represents another win in our industry-leading CNS oligonucleotide platform. C. And then very recently, we had additional positive Phase III data for olezarsen in FCS allowing, for supporting our filing for potential approval in the first half of next year. D. We've had tremendous late-stage positive readout setting us up for potential approvals for eplontersen in December this year for TTR polyneuropathy, setting us up for potential approval next year, assuming priority review for olezarsen in FCS. E. We're looking forward to new Phase III data for donidalorsen as a prophylactic treatment for hereditary angioedema in the first half of next year. F. Today, we have 9 drugs in Phase III development that are all moving on track....
